

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/553,098

Filed: November 21, 2006

Inventor(s): Jeffrey W. Strovel

Attorney Docket No.: 357074.00009

(previously 689290-253)

Title: Determining Cancer-Linked Genes and Therapeutic
Targets Using Molecular Cytogenetic Methods

Confirmation No.: 9106

Group Art Unit: 1634

Examiner: Shaw, Amanda Marie

DECLARATION UNDER 37 C.F.R. §1.132Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Colyn Cain, Ph.D., do hereby make the following declaration:

(1) I am a co-inventor of Application No.: 10/553,098 directed to *Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods*.

(2) I received a Ph.D. in Human Genetics from the University of Maryland and completed a postdoctoral clinical fellowship at the Institute of Genetic Medicine, Johns Hopkins University School of Medicine. I am certified in Clinical Cytogenetics by ABMG. I previously worked at Avalon Pharmaceuticals where I used molecular cytogenetic techniques to discover new therapeutic cancer targets.

(3) I am familiar with the invention disclosed and claimed in this patent application.


(4) Table 1 of the specification as filed provides a list of genes identified in cancerous cells as being *both* over-expressed and showing increased copy number. That is, the genes within this Table 1 are expressed at levels in cancer cells that are different from the expression levels in

non-cancer cells, and the genes within this Table 1 are amplified in cancer cells relative to non-cancer cells.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: March, 31 2011

By:


Colyn Cain, Ph.D.